RKTG/PAQR3 inhibits in vitro leukemia and prostate cancer cell proliferation and in vivo prostate tumor growth by suppressing both Ras/Raf/MEK/ERK and PI3K/AKT signaling cascades [68,73]. Here, EPHB2 is linked to prostate carcinoma.